Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Digging into the TRANSCEND studies for Bristol Myers' Breyanzi (lisocabtagene maraleucel) in follicular and mantle cell lymphoma

Ticker(s): BMY

Who's the expert?

Institution: Detroit Medical Center

Board Certified Hematologist and oncologist
Currently manages 120 CLL patients and 30 SLL patients
Has prescribed Imbruvica to as a first line treatment to ~40 patients

Interview Goal

The conversation will focus on the recent data from the two TRANSCEND studies from Bristol Myers evaluating Breyanzi (lisocabtagene maraleucel) in follicular lymphoma (Phase 2) and mantle cell lymphoma (Phase 1).

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.